At a glance
ClinicalIndex Comparison RecordN/ACompleted· 51 enrolled
Drug / intervention
Drug Eluting Balloondevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Everolimus-Coated Percutaneous Transluminal Coronary Angioplasty Catheter First in Human Clinical Investigation: A Clinical Evaluation in the Treatment of Subjects With In-Stent Restenosis of Previously-treated Coronary Artery Lesions
In Brief
A clinical study evaluating Drug Eluting Balloon for In-stent Restenosis. Completed, enrolled 51 participants across 9 sites in 4 countries.
Detailed Summary
The goal of this first in human study is to assess the safety and inhibition of restenosis of the CVT Everolimus-coated PTCA Catheter in the treatment of subjects presenting in-stent restenotic lesions in native coronary arteries.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIn-stent Restenosis
CountriesFrance, Georgia, Lithuania, Spain
Collaborators--
Timeline
N/ACompletedFinished
20222023202420252026
Enrollment StartOct 2021
Primary CompletionSep 2022
First PostedFeb 2023
Study CompletionMay 2025
TodayJul 2026
First PostedFeb 16, 2023
Enrollment StartOct 20, 2021
Primary CompletionSep 19, 2022
Study CompletionMay 8, 2025
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 3.4 years ago
Interventions
Drug Eluting Balloondevice
PCI of in-stent restenosis